Archive for the ‘Crispr’ Category

A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic conditions given its key advantages over CRISPR gene editing.

Since CRISPR-Cas9 gene editing was first reported in 2012, its promise of making gene editing faster, cheaper, and easier than ever before led to an explosion in the number of publications referring to this gene editing technology.

An increasing number of research labs and companies are aiming to translate CRISPR gene editing into therapies for genetic diseases. However, further research has unveiled that there are more limitations to using CRISPR-Cas9 to cure diseases than initially expected. For example, the technology has been reported to introduce off-target changes to the DNA, raising concerns about its safety.

In the meantime, RNA editing has emerged as an alternative to CRISPR technologies, getting a lot of attention from researchers and industry. RNA editing allows scientists to make changes in the molecules that carry the instructions needed to produce proteins, without changing the original DNA code.

One common method of RNA editing consists of using an enzyme called adenosine deaminase acting on RNA (ADAR), which uses a guide RNA sequence to identify the target RNA molecules and change one of its building blocks, or bases. This can be used to repair point mutations in the RNA instructions that would otherwise result in a damaged or even absent protein.

Although RNA editing was first described in the late 1980s, its therapeutic potential wasnt explored until 1995, when the US biotech Ribozyme Pharmaceuticals started researching it within the context of muscular dystrophy.

However, the concept of therapeutic RNA editing was quickly forgotten, only to be rediscovered nearly two decades later by German chemist Thorsten Stafforst from the University of Tbingen and the biologist Joshua Rosenthal of the Marine Biology Laboratory in Chicago, USA.

For Stafforst and Rosenthal, the timings of their respective publications on RNA editing in 2012 and 2013 were inconvenient. The news of CRISPR gene editing being possible in mammalian cells created such a buzz in the scientific community, that Stafforst himself experienced great difficulty in getting his results published. Who would need to edit RNA if we could already manipulate the DNA?

It took the FDA and EMA approval of the RNA interference drug patisiran in 2018 to revive the attention on the therapeutic potential of RNA editing. Since then, this technology seems to be experiencing momentum as it becomes increasingly clear that it might have some major advantages over CRISPR gene editing to treat human diseases.

First of all, ADAR is an enzyme naturally present in the human body. This means that for RNA editing therapies, only the guide RNA would need to be delivered. In contrast, CRISPR gene editing requires the delivery of the Cas9 protein in addition to an RNA guide. This protein is bulky and is obtained from microorganisms, which leaves it at risk of being recognized as foreign by the immune system.

An additional advantage is that guide RNAs belong to a class of drugs called antisense oligonucleotides, of which there are already six FDA-approved molecules available to treat a range of diseases. With the safety of guide RNA already established, the approval of RNA editing treatments could be significantly accelerated.

One of the strongest advantages of RNA editing is that changes to the RNA are only temporary. Concerns regarding irreversibly modifying human DNA would therefore cease with RNA editing. Even if off-target effects occur, they would disappear with time as the drug is eventually broken down and stops exerting its effects.

The biotech industry is increasingly recognizing the potential of RNA editing, with a growing number of companies and startups working in this field. Among them are ProQR, a Dutch company that focuses on treating rare genetic disorders that cause blindness; and Vico Therapeutics in Belgium, looking into spinocerebellar ataxia and Huntingtons disease.

Overseas, there is Edit Force in Japan, working in neurodegenerative conditions and cancer. In the US we find Shape Therapeutics and Locana; the latter develops treatments for motor-neuron disease and Huntingtons disease.

While these companies are raising big amounts of funding, their technology is still in the early stages. Some of them, like ProQR and Shape Therapeutics, have promising results in studies with mice, but none has tested the technology in humans yet. Although the process of RNA editing has been known since the 1980s, there are still some challenges to resolve before the technology can be taken to clinical trials.

Firstly, RNA is comparably unstable as a molecule and delicate to handle. Researchers are working on finding a delivery system that can direct the guide RNA to its target location while protecting it from degradation. Secondly, as with the RNA guides used for CRISPR gene editing, the RNA guides for RNA editing treatments can potentially cause an immune reaction, which needs to be ruled out individually before their approval.

Thirdly, RNA editing enzymes are very specific regarding which RNA bases they exchange. This means the technology is limited to a few kinds of changes, which, in turn, limits the number of conditions that it can treat, making it less attractive as a research tool when compared to CRISPR-Cas9. It will take some time until protein engineering allows us to modify RNA editing enzymes involved to expand the types of conversion they can perform.

Still, RNA editing seems to hold major promise to tackle diseases for which there is no cure available yet. Studies in mice showed results supporting RNA editing as a potentially powerful tool for genetic diseases like muscular dystrophy.

Before this technology becomes clinically viable, however, its efficiency will need to be optimized and its safety tested. At this point, it is not possible to say when, or if, RNA editing will make it to the clinic. But the latest research developments and the interest of the industry in RNA editing indicate that someday soon, these therapies might be able to help patients suffering from a wide range of diseases.

The author of this article wishes to remain anonymous

Images from Elena Resko and Shape Therapeutics

Read the original:
Overcoming the Limitations of CRISPR Gene Editing with RNA... - Labiotech.eu

With California Ag Today, Im Tim Hammerich.

UC Davis Animal Genomics Researcher Alison Van Eenennaam and her team have been working with CRISPR to try to improve cattle genetics.

Just as dairies ideally want heifer calves because they can ultimately produce milk, the beef industry wants bull calves, because they tend to be more feed efficient.

Van Eenennaam describes her teams genomic approach to solving this problem.

Van Eenenaam We did genome editing in the developing embryo of a bull and inserted a gene that's responsible for producing males. And this animal was born. His name is Cosmo. And we will know in his offspring, whether or not inheriting that particular gene results in the male appearance of animals that would otherwise be XX genotypic females. And so we haven't finished the experiment yet, but we have produced the gene-inserted genome-edited offspring, Cosmo.

Van Eenenaam says the birth of Cosmo is a big step in the project, but its not over yet.

Van Eenenaam So obviously half his offspring will be male because they'll inherit the Y chromosome, but the real ones we're interested in other ones that inherit the X chromosome, but also inherited the gene we inserted: SRY. Because our prediction is that we will actually have a male appearance in otherwise what would be XX genotypic females.

Read more from the original source:
CRISPR in Cattle - Part 2 - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Thesis

CRISPR Therapeutics (CRSP) is a high-risk, high-reward investment prospect. In my view, the market has mispriced the probability of CRISPR Therapeutics successfully utilizing the CRISPR/CAS9 platform across multiple disease states. In the most optimistic scenarios, the company could be worth several hundred billion dollars. The company is raising significant amounts of capital, which will allow it to invest across multiple disease states. I view this development extremely positively, as it comes on the heels of positive data from CTX001 and indicates the company is looking to solidify its lead in bringing CRISPR/CAS9 products to market. I am extremely bullish on the shares in the long run.

CRISPR Therapeutics was co-founded by Dr. Emmanuelle Charpentier together with Rodger Novak and Shaun Foy. In fact, Charpentier is generally credited with discovering how CRISPR/CAS9 could be applied for gene-editing purposes (along with colleague Jennifer Doudna). Currently, the company trying to apply the breakthrough gene-editing technology it's founder developed into the following disease states (per August 2020 Investor Presentation):

Hemoglobinopathies: This category includes various genetic diseases that affect the production of hemoglobin. Currently, the company has begun enrolling patients in Phase 1 trials for patients with beta-thalassemia and sickle cell disease. Both of these trials are in collaboration with Vertex Pharmaceutical (NASDAQ:VRTX) and will use the CTX001 treatment.

Immuno-oncology: This category includes drugs being developed to repurpose the human immune system in order to fight cancer. Currently, the company is developing three allogeneic CAR-T therapies for this purpose, which are enrolling patients now.

Regenerative Medicine: The company is currently researching a potential cure for Type 1 diabetes in partnership with Viacyte.

In vivo approaches: This category includes disease states, where gene-editing therapies could be applied. Currently, the company is researching cures for Glycogen Storage Disease, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1, and Cystic Fibrosis. Finally, the company has also noted it is working on additional undisclosed early-stage programs in partnership with Vertex and Bayer (OTCPK:BAYZF).

Source: August 2020 Investor Presentation

CRISPR Therapeutics pipeline appears both immature and aggressive. No therapy has progressed past a Phase 1 trial, and the company is already expanding into some of the most complex disease states. While this lack of specialization certainly presents execution risks, I believe the pipeline is well crafted. The company is expanding into diseases with larger patient population, which presents a more lucrative opportunity for therapy development. Furthermore, the company is diversifying how CRISPR/CAS9 technology will be utilized to create a therapy, as demonstrated by the difference between its CTX001 therapy, and its allogeneic CAR-T therapies.

Before moving onto the early data points, we have on efficacy, if you need a refresher on the technology, I highly recommend the ARK Invest White Paper on CRISPR. Their in-depth research coherently makes the case for why CRISPR is a superior gene-editing platform compared to existing approaches like ZFNs and TALENs.

The company currently has several data points back from its CTX001 ex vivo treatment, and the results are nothing short of stunning. For the two first Beta-Thalassemia patients treated, both are transfusion independent 5 months & 15 months after a CTX001 infusion. For reference, patient 1 averaged 34 units of packed red blood cell transfusions per year before the CTX001 infusion. Meanwhile, patient 2 required 61 units of packed red blood cell transfusions per year. For Sickle-Cell Disease, their first patient was experiencing seven vaso-occlusive crises and five packed red blood cell transfusions per year on average. After the CTX001 infusion, the patient has been vaso-occlusive crises free for nine months with zero red blood cell transfusions.

It is worth mentioning just how life-changing this therapy has already been for these patients. One beta-thalassemia patient was 19-year-old women with anemia, a low quality of life who needed multiple monthly transfusions. The disease was damaging her vital organs, and landing her trips into the hospital that was putting her life at risk. Since CTX001, these effects have subsided. The Sickle-Cell Disease patient, Victoria Gray, is a mother of three whose life was constantly put at risk from vaso-occlusive events. While scientists were initially hoping to increase her fetal hemoglobin to 20% of her total hemoglobin level, CTX001 increased that level to 46%. Additionally, a biopsy of her bone marrow cells showed that 81% of the cells contained the edited DNA, which would allow her body to maintain the higher fetal hemoglobin levels for a sustained period of time. Data aside, the patient's interview with NPR may summarize the results best, "It's wonderful. It's the change I've been waiting on my whole life".

Despite the success, there are concerns about the treatment that are yet to be addressed: 1) Is the treatment durable? The first Beta-thalassemia patient is transfusion independent after 15 months, but just how long will this effect last into the future? When the company begins to dose more patients, will they experience similar long-lasting results? The company will need to monitor its patients for a longer period of time to prove their therapies durability. 2) Is the treatment consistent? One of the chief concerns regarding gene editing is the accuracy and consistency with which companies can actually edit a patient's genome. Part of this concern is related to the actual technological process of the edit, and in that regard, CRISPR/CAS9 system is believed to be a consistent editor of DNA in cells. Additionally, a less publicized facet of the consistency concern stems from the ability to manufacture these complex treatments. In this regard, CRSIPR is one step ahead of the competition by launching a state-of-the-art manufacturing facility in Framingham, MA to support its programs.

I have been a long-time believer in gene-editing and the CRISPR platform, but I truly never anticipated CRISPR Therapeutics could release initial data this positive. I believe the company has an effective cure on its hands.

The company's Immuno-oncology ambitions rest heavily on the use of allogeneic CAR-T therapies. CRISPR Therapeutics believes that allogeneic therapies can be safely created and administered to patients, and offer greater treatment potential for patients as compared to autologous therapies. In short, autologous therapies use the patient's own cells, which are then edited and used for treatment, while allogeneic therapies use a single-source of cells that are not derived from the patient.

The companies first trial using its proprietary allogeneic CAR-T platform uses CTX110 for the treatment of CD19+ B-cell malignancies. Even though the trial is still enrolling patients, the company expects to report some top-line data for CT110 by the end of 2020. Although this readout will occur relatively soon, I think it will provide an important update on how mature the companies platform in immuno-oncology truly is. Unfortunately, due to the relatively complex nature of this disease and the treatment itself, I am not expecting the same type of blockbuster results we saw in Hemoglobinopathies, but I still expect a successful readout.

As it relates to CTX120 for the treatment of multiple myeloma and CTX130 for the treatment of solid tumors like renal cell carcinoma, the only data available is from testing on mice. However, it is worth noting that in both cases, all five mice treated with the appropriate infusion for their xenograft cancer were found to be completely cancer free. The graph below shows the observed progression for CTX120.

The company's main regenerative medicine therapy will be looking to treat Type 1 diabetes. The approach will utilize CRISPR/CAS9 to edit pluripotent stem cells for beta cell replacement, which will enable the new pancreatic cells to secrete insulin. The therapy will actually seek to leverage the technology it has developed for its allogeneic CAR-T platform in order to cure the disease. At this point, the company is still in the research stage with its partner Viacyte, so it will be quite a while before any substantial data comes from this work. Additionally, snuck into a recent press release, CRISPR announced that it is partnering with UHN, Canada's largest research hospital, in order to utilize gene-editing technology in order to turn stem cells into hepatocytes. This indicates that CRISPR is looking to extend its regenerative medicine franchise into liver diseases, which could potentially treat a large variety of patient populations

The therapies cited above are considered ex vivo treatments, as outside cells are edited and infused into the patient for treatment. In vivo therapies would directly edit the cells inside a person. This type of therapy presents higher risks and greater technological challenges for execution. Thus, as it relates to CRISPR's in vivo pipeline, I believe these therapies will need a significantly longer period of maturation until these products can successfully come to market. For the purposes of this analysis, I believe it is important to note that management is researching how to best bring these drugs to fruition, but CRISPR/CAS9 may not be the right technology to do that. Despite this risk, CEO Samarth Kulkarni has stated that he expects CRISPR Therapeutics to purchase and adapt to new technologies as they are developed, ensuring that the company will remain at the forefront of the gene-editing revolution.

CRISPR finished Q2 2020 on solid financial footing. Cash and Cash equivalents ended June 30, 2020 at $945M compared to $890M on March 30th, an increase of $55M. Financing provided $89M in cash, while a milestone payment from Vertex provided another $25M. Q2 2020 R&D expenses totaled $59M while G&A expenses were $21M, which combined for a net loss of $79.7M. With almost $1B of cash in the bank, enough to cover two years of operations, you may feel that CRISPR Therapeutics is a cash-rich company. Well, management would disagree, because on June 30th they announced another secondary share offering to raise ~$455M at $70 a share.

In my view, the capital raise is extremely prudent. Samarth expects gene-edited products to compose 30% of the global pharmaceutical market within 12 years, as stated at the William Blair Biotech Focus Conference. This implies a market opportunity of hundreds of billions of dollars, of which no company has become the global leader. This is a unique opportunity to become the market leader in pharmaceuticals and I believe CRISPR Therapeutics should raise and spend as much capital as necessary in order to capture this market. Secondly, management is once again raising capital at all-time high share prices, which I believe demonstrates a conservative management philosophy that will continue to serve shareholders well into the future.

CRISPR Therapeutics can be essentially considered a pre-revenue company, and will not have any commercial products for several years. However, for the sake of propriety, it is worth noting the potential market opportunity for a successful treatment. As noted in the company's 2019 annual report, there are estimated to be 200,000 people worldwide who are alive and registered as receiving treatment for Beta-Thalassemia, of which approximately 19,000 live in the US or Europe. Additionally, another 60,000 are born with the disease annually. For Sickle-Cell Disease, there are estimated to be 20-25 million people worldwide with the disease, of which 100,000 reside in the United States. Additionally, another 300,000 are born with the disease annually. Meanwhile, as Ark Invest noted in their white paper, the market for CAR-T therapies is expected to grow to over $100B annually. These market opportunities are exceptionally large, and this could allow CRISPR Therapeutics to generate billions of dollars annually from its lead therapies in Phase 1 trials today.

Meanwhile, from an operational standpoint, I believe CRISPR appears to be allocating its resources efficiently. Take a look at its operating expenses over the past five years. While General and Administrative costs were outpacing actual R&D when the company first started, management is now spending three times as much money on R&D as G&A. I am highly encouraged by this development, because as an investor, I want the capital being raised to be spent on value creation, not overhead. Finally, it is also worth noting that the company ended 2019 with just over 300 employees, but currently has 53 open positions. This indicates the company is hiring for massive growth, which will help it execute on its diverse array of disease programs.

CRISPR Therapeutics is my best high-risk, long-term investment idea. The initial CTX001 data has been incredible, the company is capitalizing on a surging share price, and investing heavily across multiple disease programs. CRISPR Therapeutics' current market cap is $6.3B, but any number of bullish scenario's involving multiple successful products could create a company valued in the hundreds of billions. This presents an opportunity with significant asymmetric upside for the share price if an investor is willing to take the risk.

It is also worth noting for the purposes of this article that there are several other similar companies operating in this segment of gene-editing technology, such as Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM). While CRISPR Therapeutics is generally regarded as the leader of this group, I am, in general, bullish on these other companies for two reasons: (1) I believe the bull case on CRISPR Therapeutics to be chiefly driven by the technological platform, which these other companies are also working to mature (2) I believe these shares will act as a hedge to single-stock risk, where the technological platform may succeed, but not necessarily with CRISPR's management or pipeline of products.

Source: August 2020 Investor Presentation

Disclosure: I am/we are long CRSP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I am long CRSP, EDIT, NTLA, and BEAM. I have been acquiring shares since 2017 in CRSP, and intend to continue gradually purchasing more shares. I am not an expert, and this is not financial advice.

Read the original post:
Crispr Therapeutics: My #1 High-Risk Investment Idea - Seeking Alpha

With California Ag Today, Im Tim Hammerich.

UC Davis Animal Genomics Researcher Alison Van Eenennaam has been working for five years to see if CRISPR can help us breed a line of cattle thats better tailored for the beef industrys needs.

Van Eenennaam CRISPR is a tool that can be used to introduce useful genetic variation into our cattle breeding programs. And it enables us to do targeted alterations to the genome and maybe inactivate genes that make cattle susceptible to disease, or give them the ability to be more heat tolerant. Traits that will better suit them to the environment and to have improved health.

Van Eenannaam and her team set out to see if one gene in particular could be introduced to help make the beef industry more efficient.

Van Eenannaam We're interested in seeing whether or not we could produce all male cattle for the beef industry where actually males in the feedlot sector would be the preferred sex. The same way dairy producers like female cattle to produce milk if possible, we'd like male cattle in the feedlot industry. There is a single gene called SRY that's responsible for the male developmental pathway, and we were interested in seeing whether, if we introduced that gene using CRISPR, whether we could actually produce all male offspring in the offspring of a bull.

Stay tuned for part 2 tomorrow where we introduce you to the first calf born with this gene.

More here:
CRISPR in Cattle - Part 1 - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

A New Research Published byGMAon theGlobal CRISPR Technology Market (COVID 19 Version)in various regions to produce more than 200+ page reports. This study is a perfect blend of qualitative and quantifiable information highlighting key market developments, industry and competitors challenges in gap analysis and new opportunities and may be trending in theGlobal CRISPR Technology Market. Some are part of the coverage and are the core and emerging players being profiledThermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen.

Get Free Sample PDF Copy ofGlobal CRISPR Technology MarketReport @:grandmarketanalytics.com/Request-For-Sample-Report?/Global-CRISPR-Technology-Market-&id=72241

What we provide inGlobal CRISPR Technology MarketResearch Report?

Get Up to 40 % Discount on Enterprise Copy@grandmarketanalytics.com/Check-Discount-On-Report?/Global-CRISPR-Technology-Market-&id=72241

KEY BENEFITS

TheGlobal CRISPR Technology Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

TheGlobal CRISPR Technology Marketreport provides an in-depth review of industry dynamics inCRISPR Technology, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on theCRISPR Technologyreport.

Industry players strategic analysis and industry position in theGlobal CRISPR Technology Market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

Note: Please Share Your Budget on Call/Mail We will try to Reach your Requirement @Phone:+1 (925) 478-7203/Email:[emailprotected]

Make the Inquiry forGlobal CRISPR Technology MarketReport before Purchase @:grandmarketanalytics.com/Reports-Description-And-Details?/Global-CRISPR-Technology-Market-&id=72241

Quantitative data:

Breakdown of market data by main region & application / end-user

By typeEnzymes, Kits, gRNA, Libraries, Design Tools, ,

Global CRISPR Technology MarketReport-specific sales and growth rates for applicationsBiomedical, Agricultural, , (historical & forecast)

Global CRISPR Technology MarketProfits by sector and growth rate (history and forecast)

Global CRISPR Technology Marketsize and rate of growth, application and type (Past and Projected)

Global CRISPR Technology MarketSales income, volume and growth rate Y-O-Y (base year)

Qualitative data: Includes factors affecting or influencing market dynamics and market growth. To list some names in related sections

Industry overview

GlobalGlobal CRISPR Technology Marketgrowth driver

GlobalGlobal CRISPR Technology Markettrends

Incarceration

Global CRISPR Technology MarketOpportunity

Market entropy ** [specially designed to emphasize market aggressiveness]

Fungal analysis

Porter Five Army Model

Research Methodology:

Primary Research:

We interviewed various key sources of supply and demand in the course of thePrimary Researchto obtain qualitative and quantitative information related to this report. Main sources of supply include key industry members, subject matter experts from key companies, and consultants from many major firms and organizations working on theGlobal CRISPR Technology Market.

Secondary Research:

Secondary Researchwas performed to obtain crucial information about the business supply chain, the company currency system, global corporate pools, and sector segmentation, with the lowest point, regional area, and technology-oriented perspectives. Secondary data were collected and analyzed to reach the total size of the market which the first survey confirmed.

Customization Available for Following Regions & Country:North America, South & Central America, Middle East & Africa, Europe, Asia-Pacific

Buy Full Copy GlobalGlobal CRISPR Technology MarketReport 2020-2029 @grandmarketanalytics.com/payment/checkout?reportid=72241

The research provides answers to the following key questions:

1) Who are the key Top Key players in the GlobalGlobal CRISPR Technology Market Report?

Following are list of players:Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen.

Note: Regional Breakdown & Sectional purchase Available We provide Pie charts Best Customize Reports As per Requirements.

2) Which Are the Main Key Regions Cover in Reports?

Geographically, this report is divided into several main regions, consumption, revenue (million USD) andGlobal CRISPR Technology Marketshare and growth rate in these regions, from 2019 to 2029 (predicted), covering North America, Europe, Asia-Pacific, etc.

3) What is the projected market size & market growth rate for the 2019-2029 periodGlobal CRISPR Technology Marketindustry?

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so reach our business development executive @[emailprotected]

4) Can I include additional segmentation / market segmentation?

Yes. Additional granularity / market segmentation may be included depending on data availability and difficulty of survey. However, you should investigate and share detailed requirements before final confirmation to the customer.

5) What Is impact of COVID 19 on GlobalGlobal CRISPR Technology Market industry?

Before COVID 19Global CRISPR Technology MarketMarket Size Was XXX Million $ & After COVID 19 Excepted to Grow At a X% & XXX Million $.

TOC for GlobalGlobal CRISPR Technology MarketResearch Report is:

Section 1: Global Market ReviewGlobal CRISPR Technology Market(20132029)

Defining

Description

Classified

Applications

Facts

Chapter 2: Market Competition by Players/Suppliers 2013 and 2019

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2013-2019)

Sales

Revenue and market share

Chapter 4, 5 and 6: GlobalGlobal CRISPR Technology Marketby Type, Application & Players/Suppliers Profiles (2013-2019)

Continued..

Contact Us:GRAND MARKET ANALYTICSMark(Head of Business Development)Phone:+1 (925) 478-7203Email:[emailprotected]

Read the original here:
CRISPR Technology Market Demand & SWOT Analysis By 2029: Key Players Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies...

Gene Editing Service Market 2020

The Gene Editing Service survey report contains valuable insights into the industry. The Gene Editing Service report begins with an understanding of the current market scenario, and goes on to describe the products available in the market, along with their different applications. The report also discusses the manufacturing technology used for production processes and how the availability of the same can affect the market. Our Gene Editing Service survey report details the scope of growth of the industry and also looks into the different emerging trends in the market. Our report covers the forecast period 2020-2026. Our Gene Editing Service survey also provides a predicted market valuation for the forecast period, as well as a projected valuation by the end of the forecast period.

The report provides and in-depth analysis of the industrys tools, mechanisms, and sales and distribution methods, which significantly influence the scope for growth. With this information, the segmentation of the market is understood in a much clearer way. The global Gene Editing Service is influenced by a number of factors such as environmental fluctuations, socio-economic changes, new policies and regulations introduced by the government, and much more. The report also seeks to provide the reader with information regarding the key players in the Gene Editing Service, and how they have maintained their market shares.

The global Gene Editing Service survey report includes a section that details the segmentation of the industry and the different elements that influence growth. We provide a regional analysis to determine the key players based on geographical area. The report also includes important industry updates and news that can help the reader gather a more relevant understanding of the market, as well as its growth prospects.

The study encompasses profiles of major companies operating in the Capital Lease Market. Key players profiled in the report includes: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery, Genscript Biotech, GeneCopoeia, Integrated DNA Technologies, Eurofins Genomics, DNA 2.0 (ATUM), BBI Life Sciences, Genewiz, Gene Oracle, SBS Genetech, and Bio Basic

The final report will add the analysis of the Impact of Covid-19 in this report Gene Editing Service industry.

Get a Sample Copy Of Gene Editing Service Market @ https://www.reportsandmarkets.com/sample-request/global-gene-editing-service-market-research-by-type-end-use-and-region-covid-19-version?utm_source=thedailychronicle&utm_medium=36

Latest industry news

The global Gene Editing Service report survey includes the latest updates and news from the industry. The information provided will include the latest trends in the market, the release of new and innovative technology, arrival of new products, impact of governmental regulations on sales, and much more. The section will also include details of partnerships, acquisitions, mergers, and takeovers amongst the key players in the industry, and how this can alter the growth prospects.

Gene Editing Service Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Gene Editing Service Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Gene Editing Service market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Gene Editing Service market by identifying its various sub segments.

Focuses on the key global Gene Editing Service players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Gene Editing Service with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Gene Editing Service submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Gene Editing Service Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents: Gene Editing Service Market

Chapter 1: Overview of Gene Editing Service Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Inquiry Before [emailprotected] https://www.reportsandmarkets.com/sample-request/global-gene-editing-service-market-research-by-type-end-use-and-region-covid-19-version?utm_source=thedailychronicle&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the original post:
Gene Editing Service Market (Impact of COVID-19) Top Growing Companies: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo...

This intricately designed endeavor offered to highlight the primary developments in the Global CRISPR Technology Market are poised to equip report readers and research practitioners with high end technical nuances about the major growth inducing developments in the CRISPR Technology market that subsequently decide future prospects and key business discretion on the part of market players comprising both established as well as amateur ones aiming to strike timely disruption in the discussed CRISPR Technology market.

Request a sample of CRISPR Technology Market report @ https://www.orbisresearch.com/contacts/request-sample/4890422

In further discussions, the report continues to extend minute insightful cues to its readers market players, their growth objectives, long and short-term business goals and the like, based on which highly successful business ventures are mediated for maximum return on investments in global CRISPR Technology market.

The report reveals dynamic information about various knowledge factors such as sales volume and bulk production, pricing matrix and sales figures, overall growth review and margin, chances of growth in the future and their range amongst other additional growth determinants that influence growth in the CRISPR Technology market.

Key Manufacturers Analysis:

Thermo Fisher ScientificMerck KGaAGenScriptIntegrated DNA Technologies (IDT)Horizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

A thorough analytical documentation comprising market classification, supply chain nuances, best industry practices adhered by frontline players, minute methodical applications as well as a complete outlook of the competition spectrum have been minutely addressed in this section of the CRISPR Technology market report to influence a highly profitable market growth trajectory through the forecast span.

Access full report @ https://www.orbisresearch.com/reports/index/global-crispr-technology-market-report-2020

On the basis of the aforementioned market relevant information portrayed in the report, this illustrative research report also identifies the market segments that leverage high revenue growth in the CRISPR Technology market. The market identifies type and application as prominent growth steering factors that continue to remain prominent influencing growth the CRISPR Technology market.

CRISPR Technology market Segmentation by Type:

EnzymesKitsgRNALibrariesDesign Tools

CRISPR Technology market Segmentation by Application:

BiomedicalAgricultural

This section of the report is crucial in harnessing report readers understanding to decode, identify and pinpoint the segment in the CRISPR Technology market that inculcates revenue maximization without having any constraints that in due course hinder growth in global CRISPR Technology market.

An Analysis of the Geographical Span:

Besides a macroscopic analysis based on regional segmentation, the report also focuses on country-wise review of the CRISPR Technology market. This extensive research report compilation highlighting the details about market prognosis attempts to also unearth some of the concurrent developments and forces that strike growth in the global CRISPR Technology market.

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Reasons to Buy the Report:

1. The CRISPR Technology market report is a ready-to-go market specific document encompassing regional overview, opportunity mapping, and competition analysis.2. A critical review of dominant market trends, leading market strategies as well as best industry practices has also been tagged in the CRISPR Technology market report.3. The report is focusing specifically across a range of key development areas such as dynamic segmentation, cross sectional analysis of the target market.4. Access to extensive overview of the CRISPR Technology market at a multi-faceted perspective.5. Focus on real time market growth status to encourage accurate market specific decisions.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4890422

ABOUT US:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

CONTACT US:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Read more:
Global CRISPR Technology Market Trends, Industry Demand, Growth Analysis and 2025 Forecast Overview, Top Players Analysis- Thermo Fisher Scientific,...

New Jersey, United States,- The CRISPR and Cas Genes Market is predicted by Verified Market Researchs report to find players focusing on new product development to secure a strong position in terms of revenue sharing. Strategic collaboration can be a powerful way to bring new products to the market. The level of competition observed in the market may increase.

This research report categorizes the global market by players/brands, regions, types, and applications. The report also analyzes the global market status, competitive landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, five forces of distributors, and porters.

The latest 2020 edition of this report reserves the right to provide further comments on the latest scenarios, recession, and impact of COVID-19 on the entire industry. It also provides qualitative information on when the industry can rethink the goals the industry is taking to address the situation and possible actions.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

CRISPR and Cas Genes Market Segment Analysis-

The research report includes specific segments by Type and Application. Each type provides information about the production during the forecast period of 2015 to 2027. The application segment also provides consumption during the forecast period of 2015 to 2027. Understanding the segments helps in identifying the importance of different factors that aid market growth.

CRISPR and Cas Genes Market, By Product

Kits & Enzymes Libraries Design Tool Antibodies Others

CRISPR and Cas Genes Market, By Application

Biomedical Agricultural Other

CRISPR and Cas Genes Market, By End-User

Biotechnology & Pharmaceutical Companies Academic & Government Research Institutes Contract Research Organizations Others

The study analyses the following key business aspects:

Analysis of Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the CRISPR and Cas Genes market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the CRISPR and Cas Genes market.

Market Forecasts:Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the CRISPR and Cas Genes market.

Regional Growth Analysis:All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis:The report provides accurate and reliable forecasts of the market share of important segments of the CRISPR and Cas Genes market. Market participants can use this analysis to make strategic investments in key growth pockets of the CRISPR and Cas Genes market.

Business Opportunities in Following Regions and Countries:

North America (United States, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia, and Australia)

Latin America (Brazil, Argentina, and Colombia)

How will the report assist your business to grow?

The document offers statistical data about the value (US $) and size (units) for the CRISPR and Cas Genes industry between 2020 to 2027.

The report also traces the leading market rivals that will create and influence the CRISPR and Cas Genes business to a greater extent.

Extensive understanding of the fundamental trends impacting each sector, although greatest threat, latest technologies, and opportunities that could build the global CRISPR and Cas Genes market both supply and offer.

The report helps the customer to determine the substantial results of major market players or rulers of the CRISPR and Cas Genes sector.

Reason to Buy this Report:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global CRISPR and Cas Genes Market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in CRISPR and Cas Genes Market, thereby allowing players to develop effective long term strategies.

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Excerpt from:
CRISPR and Cas Genes Market Size By Product Analysis, By Application, By End-Users, By Regional Outlook, By Top Companies and Forecast to 2027 -...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Craig W. Stevens, Oklahoma State University

(THE CONVERSATION) Even as the COVID-19 pandemic cripples the economy and kills hundreds of people each day, there is another epidemic that continues to kill tens of thousands of people each year through opioid drug overdose.

Opioid analgesic drugs, like morphine and oxycodone, are the classic double-edged swords. They are the very best drugs to stop severe pain but also the class of drugs most likely to kill the person taking them. In a recent journal article, I outlined how a combination of state-of-the-art molecular techniques, such as CRISPR gene editing and brain microinjection methods, could be used to blunt one edge of the sword and make opioid drugs safer.

I am a pharmacologist interested in the way opioid drugs such as morphine and fentanyl can blunt pain. I became fascinated in biology at the time when endorphins natural opioids made by our bodies were discovered. I have been intrigued by the way opioid drugs work and their targets in the brain, the opioid receptors, for the last 30 years. In my paper, I propose a way to prevent opioid overdoses by modifying an opioid users brain cells using advanced technology.

Opioid receptors stop breathing

Opioids kill by stopping a person from breathing (respiratory depression). They do so by acting on a specific set of respiratory nerves, or neurons, found in the lower part of the brain that contain opioid receptors. Opioid receptors are proteins that bind morphine, heroin and other opioid drugs. The binding of an opioid to its receptor triggers a reaction in neurons that reduces their activity. Opioid receptors on pain neurons mediate the pain-killing, or analgesic, effects of opioids. When opioids bind to opioid receptors on respiratory neurons, they slow breathing or, in the case of an opioid overdose, stop it entirely.

Respiratory neurons are located in the brainstem, the tail-end part of the brain that continues into the spine as the spinal cord. Animal studies show that opioid receptors on respiratory neurons are responsible for opioid-induced respiratory depression the cause of opioid overdose. Genetically altered mice born without opioid receptors do not die from large doses of morphine unlike mice with these receptors present.

Unlike laboratory mice, humans cannot be altered when embryos to remove all opioid receptors from the brain and elsewhere. Nor would it be a good idea. Humans need opioid receptors to serve as the targets for our natural opioid substances, the endorphins, which are released into the brain during times of high stress and pain.

Also, a total opioid receptor knockout in humans would leave that person unresponsive to the beneficial pain-killing effects of opioids. In my journal article, I argue that what is needed is a selective receptor removal of the opioid receptors on respiratory neurons. Having reviewed the available technology, I believe this can be done by combining CRISPR gene editing and a new neurosurgical microinjection technique.

CRISPR to the rescue: Destroying opioid receptors

CRISPR, which is an acronym for clustered regularly interspaced short palindromic repeats, is a gene editing method that was discovered in the genome of bacteria. Bacteria get infected by viruses too and CRISPR is a strategy that bacteria evolved to cut-up the viral genes and kill invading pathogens.

The CRISPR method allows researchers to target specific genes expressed in cell lines, tissues, or whole organisms, to be cut-up and removed knocked out or otherwise altered. There is a commercially available CRISPR kit which knocks out human opioid receptors produced in cells that are grown in cell cultures in the lab. While this CRISPR kit is formulated for in vitro use, similar conditional opioid receptor knock-out techniques have been demonstrated in live mice.

To knockout opioid receptors in human respiratory neurons, a sterile solution containing CRISPR gene-editing molecules would be prepared in the laboratory. Besides the gene-editing components, the solution contains chemical reagents that allow the gene-editing machinery to enter the respiratory neurons and make their way into the nucleus and into the neurons genome.

How does one get the CRISPR opioid receptor knockout solution into a persons respiratory neurons?

Enter the intracranial microinjection instrument (IMI) developed by Miles Cunningham and his colleagues at Harvard. The IMI allows for computer-controlled delivery of small volumes of solution at specific places in the brain by using an extremely thin tube about twice the diameter of a human hair that can enter the brain at the base of the skull and thread through brain tissue without damage.

The computer can direct the robotic placement of the tube as it is fed images of the brain taken before the procedure using MRI. But even better, the IMI also has a recording wire embedded in the tube that allows measurement of neuronal activity to identify the right group of nerve cells.

Because the brain itself feels no pain, the procedure could be done in a conscious patient using only local anesthetics to numb the skin. Respiratory neurons drive the breathing muscles by firing action potentials which are measured by the recording wire in the tube. When the activity of the respiratory neurons matches the breathing movements by the patients, the proper location of the tube is confirmed and the CRISPR solution injected.

The call for drastic action

Opioid receptors on neurons in the brain have a half-life of about 45 minutes. Over a period of several hours, the opioid receptors on respiratory neurons would degrade and the CRISPR gene-editing machinery embedded in the genome would prevent new opioid receptors from appearing. If this works, the patient would be protected from opioid overdose within 24 hours. Because the respiratory neurons do not replenish, the CRISPR opioid receptor knockout should last for life.

With no opioid receptors on respiratory neurons, the opioid user cannot die from opioid overdose. After proper backing from National Institute on Drug Abuse and leading research and health care institutions, I believe CRISPR treatment could enter clinical trials in between five to 10 years. The total cost of opioid-involved overdose deaths is about US$430 billion per year. CRISPR treatment of only 10% of high-risk opioid users in one year would save thousands of lives and $43 billion.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Intracranial microinjection of CRISPR solutions might seem drastic. But drastic actions that are needed to save human lives from opioid overdoses. A large segment of the opioid overdose victims are chronic pain patients. It may be possible that chronic pain patients in a terminal phase of their lives and in hospice care would volunteer in phase I clinical trials for the CRISPR opioid receptor knockout treatment I propose here.

Making the opioid user impervious to death by opioids is a permanent solution to a horrendous problem that has resisted efforts by prevention, treatment and pharmacological means. Steady and well-funded work to prove the CRISPR method, first with preclinical animal models then in clinical trials, is a moonshot for the present generation of biomedical scientists.

This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/how-gene-editing-a-persons-brain-cells-could-be-used-to-curb-the-opioid-epidemic-143165.

Excerpt from:
How gene editing a person's brain cells could be used to curb the opioid epidemic - Huron Daily Tribune

Dublin, Aug. 04, 2020 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report ScopeThe report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/8msd9m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original:
CRISPR Technology Market to Grow by 20.91% in 2020, Accelerated by the Outbreak of COVID-19 - Industry Projections to 2030 - Yahoo Finance

The Regeneron Science Talent Search (STS) alumni community is an illustrious group who hold many honors. This years finalists had the opportunity to hear from one of the many accomplished Society alumni, Feng Zhang (ISEF 1998-1999, STS 2000), at a virtual version of an annual STS traditionthe Alumni Dinner. Each year a distinguished alumnus is invited to speak to the current class. Feng was in the same position as the students when he competed and heard from STS alumni who came before him. Returning to pay it forward and inspire this cohort with his insights as a successful molecular biologist focused on developing tools to improve human health, Feng spoke to the Regeneron STS 2020 finalists about his work with CRISPR-Cas9 systems and some of its applications.

Since competing in 2000, Feng has helped develop bacterial tools for gene editing and diagnostics. One of the really exciting advances over the past decade-plus has been the completion of the human genome, he said. By using genomics, scientists are now rapidly learning about what causes health problems and what can potentially be used as a way to treat illnesses.

Out of its many uses, CRISPRs potential as a therapeutic is most tantalizing to researchers and the public, but Feng cautioned against hasty adoption. One of the ongoing challenges, especially surrounding the development of gene editing and more broadly, biotechnology, is to also think about bioethics. STS finalist, Amogh Bhatnagar asked Feng if there should be any governmental regulations for the use of CRISPR. Another finalist, Jake Yasonik, wanted to know if gene-edited babies would become the norm in the future. In acknowledging the complex nature of these questions, Feng stressed the importance of involving the entire scientific community for input. Different groups have different opinions and its really important to have discussions and have all these different groups come up with a consensus for how to go about using the technology.

Ultimately, it will be up to the finalists to have these important conversations. As you go through college and training, you will become leaders in scientific, political, ethical or medical professions. Really think about these issues, Feng encouraged. These are the things that will impact humanity in a very irreversible way going forward.

Based on Fengs conversation with the finalists, it is clear more scientific innovation is possible. Theres so much out there to explore. Its very exciting, he expressed. Were really in a golden age where theres so much data and computational resources. We are beginning to learn so much more about the natural world and we can also try to make something useful out of it. When STS finalist, Alina Pollner, asked about his research experience, Feng had these words of wisdom to share: In science, you will have many eureka moments. Once you have one, you will yearn for another, its almost like getting addicted. Thats really the joy of doing science.

Read the rest here:
CRISPR pioneer and STS alumnus on the "joy of doing science" - Science News for Students

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Craig W. Stevens, Oklahoma State University

(THE CONVERSATION) Even as the COVID-19 pandemic cripples the economy and kills hundreds of people each day, there is another epidemic that continues to kill tens of thousands of people each year through opioid drug overdose.

Opioid analgesic drugs, like morphine and oxycodone, are the classic double-edged swords. They are the very best drugs to stop severe pain but also the class of drugs most likely to kill the person taking them. In a recent journal article, I outlined how a combination of state-of-the-art molecular techniques, such as CRISPR gene editing and brain microinjection methods, could be used to blunt one edge of the sword and make opioid drugs safer.

I am a pharmacologist interested in the way opioid drugs such as morphine and fentanyl can blunt pain. I became fascinated in biology at the time when endorphins natural opioids made by our bodies were discovered. I have been intrigued by the way opioid drugs work and their targets in the brain, the opioid receptors, for the last 30 years. In my paper, I propose a way to prevent opioid overdoses by modifying an opioid users brain cells using advanced technology.

Opioid receptors stop breathing

Opioids kill by stopping a person from breathing (respiratory depression). They do so by acting on a specific set of respiratory nerves, or neurons, found in the lower part of the brain that contain opioid receptors. Opioid receptors are proteins that bind morphine, heroin and other opioid drugs. The binding of an opioid to its receptor triggers a reaction in neurons that reduces their activity. Opioid receptors on pain neurons mediate the pain-killing, or analgesic, effects of opioids. When opioids bind to opioid receptors on respiratory neurons, they slow breathing or, in the case of an opioid overdose, stop it entirely.

Respiratory neurons are located in the brainstem, the tail-end part of the brain that continues into the spine as the spinal cord. Animal studies show that opioid receptors on respiratory neurons are responsible for opioid-induced respiratory depression the cause of opioid overdose. Genetically altered mice born without opioid receptors do not die from large doses of morphine unlike mice with these receptors present.

Unlike laboratory mice, humans cannot be altered when embryos to remove all opioid receptors from the brain and elsewhere. Nor would it be a good idea. Humans need opioid receptors to serve as the targets for our natural opioid substances, the endorphins, which are released into the brain during times of high stress and pain.

Also, a total opioid receptor knockout in humans would leave that person unresponsive to the beneficial pain-killing effects of opioids. In my journal article, I argue that what is needed is a selective receptor removal of the opioid receptors on respiratory neurons. Having reviewed the available technology, I believe this can be done by combining CRISPR gene editing and a new neurosurgical microinjection technique.

CRISPR to the rescue: Destroying opioid receptors

CRISPR, which is an acronym for clustered regularly interspaced short palindromic repeats, is a gene editing method that was discovered in the genome of bacteria. Bacteria get infected by viruses too and CRISPR is a strategy that bacteria evolved to cut-up the viral genes and kill invading pathogens.

The CRISPR method allows researchers to target specific genes expressed in cell lines, tissues, or whole organisms, to be cut-up and removed knocked out or otherwise altered. There is a commercially available CRISPR kit which knocks out human opioid receptors produced in cells that are grown in cell cultures in the lab. While this CRISPR kit is formulated for in vitro use, similar conditional opioid receptor knock-out techniques have been demonstrated in live mice.

To knockout opioid receptors in human respiratory neurons, a sterile solution containing CRISPR gene-editing molecules would be prepared in the laboratory. Besides the gene-editing components, the solution contains chemical reagents that allow the gene-editing machinery to enter the respiratory neurons and make their way into the nucleus and into the neurons genome.

How does one get the CRISPR opioid receptor knockout solution into a persons respiratory neurons?

Enter the intracranial microinjection instrument (IMI) developed by Miles Cunningham and his colleagues at Harvard. The IMI allows for computer-controlled delivery of small volumes of solution at specific places in the brain by using an extremely thin tube about twice the diameter of a human hair that can enter the brain at the base of the skull and thread through brain tissue without damage.

The computer can direct the robotic placement of the tube as it is fed images of the brain taken before the procedure using MRI. But even better, the IMI also has a recording wire embedded in the tube that allows measurement of neuronal activity to identify the right group of nerve cells.

Because the brain itself feels no pain, the procedure could be done in a conscious patient using only local anesthetics to numb the skin. Respiratory neurons drive the breathing muscles by firing action potentials which are measured by the recording wire in the tube. When the activity of the respiratory neurons matches the breathing movements by the patients, the proper location of the tube is confirmed and the CRISPR solution injected.

The call for drastic action

Opioid receptors on neurons in the brain have a half-life of about 45 minutes. Over a period of several hours, the opioid receptors on respiratory neurons would degrade and the CRISPR gene-editing machinery embedded in the genome would prevent new opioid receptors from appearing. If this works, the patient would be protected from opioid overdose within 24 hours. Because the respiratory neurons do not replenish, the CRISPR opioid receptor knockout should last for life.

With no opioid receptors on respiratory neurons, the opioid user cannot die from opioid overdose. After proper backing from National Institute on Drug Abuse and leading research and health care institutions, I believe CRISPR treatment could enter clinical trials in between five to 10 years. The total cost of opioid-involved overdose deaths is about US$430 billion per year. CRISPR treatment of only 10% of high-risk opioid users in one year would save thousands of lives and $43 billion.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Intracranial microinjection of CRISPR solutions might seem drastic. But drastic actions that are needed to save human lives from opioid overdoses. A large segment of the opioid overdose victims are chronic pain patients. It may be possible that chronic pain patients in a terminal phase of their lives and in hospice care would volunteer in phase I clinical trials for the CRISPR opioid receptor knockout treatment I propose here.

Making the opioid user impervious to death by opioids is a permanent solution to a horrendous problem that has resisted efforts by prevention, treatment and pharmacological means. Steady and well-funded work to prove the CRISPR method, first with preclinical animal models then in clinical trials, is a moonshot for the present generation of biomedical scientists.

This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/how-gene-editing-a-persons-brain-cells-could-be-used-to-curb-the-opioid-epidemic-143165.

Go here to read the rest:
How gene editing a person's brain cells could be used to curb the opioid epidemic - Thehour.com

Image: Mammoths CRISPR-based Covid test (Photo courtesy of Mammoth Biosciences)

The award will help scale Mammoths CRISPR-based DETECTR test onto high-throughput automated platforms in commercial labs for COVID-19 diagnostics at an accelerated rate, increasing access to accurate tests with faster turnaround across the US. Mammoths SARS-CoV-2 DETECTRTM assay uses CRISPR technology, which provides a simpler workflow and significantly faster turnaround time compared to conventional PCR methods.

With a USD 1.5 billion investment from federal stimulus funding, the RADx initiative infuses funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing. The Rapid Acceleration of Diagnostics Tech (RADx Tech) program specifically aims to support the development and commercialization of innovative technologies to significantly increase the US testing capacity for SARS-CoV-2. With the support of the RADx program, Mammoth will scale the manufacturing of its proprietary DETECTR platform to provide a high-throughput, sample-to-answer turnkey solution for commercial laboratories to enable a multi-fold increase in testing capacity.

CRISPR has the potential to help curb the COVID-19 pandemic and relieve the testing shortage, said Trevor Martin, Ph.D., co-founder and CEO of Mammoth Biosciences. We are honored to receive this support for our CRISPR-based platform to bring high-throughput, accurate testing to more people, at a time when its needed most.

This is an exciting milestone, said Bruce Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and leader of RADx Tech, one of four components of the NIH RADx initiative. It will help increase US testing capacity exponentially. Game-changing technologies emerging from our RADx pipeline will inform public health measures to stop the spread of the virus and leave us better equipped to address future pathogens and other diseases.

Related Links:Mammoth Biosciences

The rest is here:
Mammoth Biosciences' CRISPR SARS-CoV-2 Diagnostic Platform Becomes First CRISPR-Based Initiative to Be Funded by NIH - HospiMedica

ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August:

William Blair Biotech Focus ConferenceDate: Thursday, August 6, 2020Panel: 1:00 p.m. ET

Canaccord Genuity 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Fireside chat: 2:30 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

Read the original here:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Written by Abhishek De, Edited by Explained Desk | New Delhi | Updated: August 5, 2020 9:45:10 am Covid-19 testing types, process: A member of the Brooklyn Hospital Center COVID-19 testing team calls in the next patient in line in the Brooklyn borough of New York (AP)

With experts predicting the demand for Covid-19 tests in the US to be millions more per day above current levels in the coming weeks, the government has awarded contracts worth $248.7 million to seven biomedical firms to produce next-generation tests under its Rapid Acceleration of Diagnostics (RADx) initiative.

The aim behind the initiative is to significantly increase the number, type and availability of tests by millions per week by fall. According to the National Institutes of Health (NIH), the seven firms have already received Emergency Use Authorisation from the US Food and Drug Authority (FDA) after they were found successful in the first phase of trials.

While one test uses the gene-editing technique called CRISPR to spot SARS-CoV-2, another uses a technique for scanning the genetic code to see if someone has contracted the virus. Another uses saliva samples rather than time-consuming swab tests while a fourth uses a hand-held device that produces results within 30 minutes.

The development comes even as the US reported the biggest number of new cases of any month in July since the pandemic began, with more than 1.9 million new cases, according to data from Johns Hopkins University.

The NIH launched the RADx programme on April 29 days after receiving an emergency appropriation of $1.5 billion from Congress to support innovative technologies to make millions of rapid Covid-19 tests. The seven firms were chosen from over 650 applicants and 31 projects.

While the US has conducted more Covid-19 tests than any other country, more than 60 million, there have been reports that Americans still continue to wait in queues to get tested and results get delayed by weeks. The RADx initiative will help develop new tests that will allow students, teachers and other workers to get tested frequently, allowing the safe re-opening of educational institutions and bringing back normal economic activity. The initiative is aiming at approximately 6 million daily tests in the United States by December.

Mesa Biotech: The company has developed a test that employs a hand-held RT-PCR device and a compact, single-use cartridge that detects viral RNA at the point of care. Named Accula SARS-CoV-2 test, one can see the results from the removable cartridge in 30 minutes.

Quidel: This is also a point-of-care test and has been identified for use in nursing homes or pharmacies. Named Quidel Sofia SARS Antigen FIA test, a lateral flow immunoassay, it uses analysers equipped with advanced fluorescence detection with an ultraviolet LED energy source. The analysers give results within 15 minutes.

Talis Biomedical: Capable of returning a result under 30 minutes, the Talis One Covid-19 test uses a multiplexed cartridge to detect SARS-CoV-2 through isothermal amplification of viral RNA and an optical detection system.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Ginkgo Bioworks: The Boston-based firm uses next-generation sequencing technologies to process tens of thousands of individual tests at once and will provide end-to-end sample collection and report results within 24-48 hours. The company is expected scale up to 50,000 tests per day in September and 100,000 per day by the end of the year.

Helix OpCo: The Covid-19 test by Helix uses nasal swabs to collect samples that can be processed in very volumes at once and can give results within 24-48 hours using a combination of sophisticated automation processes.

Fluidigm: The California-based firm has developed a diagnostic molecular test integrated with fluidic chips that detects SARS-CoV-2 from saliva specimens. The high-throughput test, named Advanta Dx SARS-CoV-2 RT-PCR Assay, does not need a viral RNA extraction kit.

Mammoth Biosciences Inc: The Covid-19 test, named SARS-CoV-2 DETECTR assay, uses gene-editing CRISPR technology, which provides a simpler workflow and faster turnaround time compared to conventional PCR tests.

The CRISPR technology can detect even a small extract of SARS-CoV-2 genetic material in a nose, mouth or throat swab, or in fluid from the lungs. If the viruss genetic material is detected, the CRISPR enzyme generates a fluorescent glow.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the original post:
Explained: The new and quicker Covid-19 tests approved under the US RADx scheme - The Indian Express

Dublin, Aug. 04, 2020 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report ScopeThe report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/8msd9m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:
CRISPR Technology Market to Grow by 20.91% in 2020, Accelerated by the Outbreak of COVID-19 - Industry Projections to 2030 - GlobeNewswire

DUBLIN--(BUSINESS WIRE)--The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report Scope

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/71fzdf

Read the original here:
Global CRISPR Technology Market Outlook 2020-2030 - Industry Driven by CRISPR Technology Being Used as a Diagnostic Tool for COVID-19 -...

Global CRISPR gene-editing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the CRISPR gene-editing market for Global, Europe, North America, Asia-Pacific, South America, and the Middle East & Africa.

Global CRISPR Gene-Editing Market report performs systematic gathering, recording and analysis of data about the issues related to the marketing of goods and services and serves the businesses with an excellent market research report. The report provides intelligent solutions to complex business challenges and commences an effortless decision-making process. The report analyses and evaluates the important industry trends, market size, market share estimates, and sales volume with which industry can speculate the strategies to increase return on investment (ROI). In the Global CRISPR Gene-Editing Market document, the statistics have been represented in the graphical format for an unambiguous understanding of facts and figures.

CRISPR gene-editing marketis rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Key Market Players:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the CRISPR Gene-Editing Industry

High prevalence of cancer worldwide is driving the growth of this marketJoint ventures by biotechnical companies for the advancement of genetic engineering for the development of CRISPR worldwide can also boost the market growthExpanding the application of CRISPR technology by innovative research from the different academic organizations also enhances the market growth

High finance in research and development also acts as a driving factor in the growth of this marketProbable mistreatment of CRISPR gene editing device and CRISPR/Cas genome editing device is restricting the growth for the marketScientific and major technical challenges for the production of disease specific novel CRISPR gene editing can also hamper the market growthLack of healthcare budget in some middle-income countries restricts the market growth

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

The titled segments and sub-section of the market are illuminated below:

By Therapeutic

OncologyAutoimmune/Inflammatory

By Application

Genome EngineeringDisease ModelsFunctional GenomicsOthers

By Technology

CRISPR/Cas9Zinc Finger NucleasesOthers

By Services

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System ProductsOthers

By Products

GenCrispr/Cas9 kitsGenCrispr Cas9 AntibodiesGenCrispr Cas9 EnzymesOthers

By End-Users

Biotechnology & Pharmaceutical CompaniesAcademic & Government Research InstitutesContract Research OrganizationsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

How will the report help new companies to plan their investments in the CRISPR Gene-Editing market?

The CRISPR Gene-Editing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crispr-gene-editing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Follow this link:
Global CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo...

The global CRISPR and Cas Genes Market Report 2020 was prepared to provide the market landscape and unlimited guidelines for the current market size, market share, driving factors, Trends, progressive growth and the dominant players of the CRISPR and Cas Genes Market . The report provides top manufacturers, distributors, dealers and dealers with general information about the market. It will help you to understand the product scope, the market overview, the driving force of the market, technological progress, market risk, opportunities and research results.

Market Report world has monitored the CRISPR and Cas Genes Market for the new Research Areas industrial market CRISPR and Cas Genes Market was valued at USD 1.35 Billion in 2019 and is projected to reach USD 4.53 Billion by 2027, growing at a CAGR of 16.36 % from 2020 to 2027.

Our Reports on the CRISPR and Cas Genes Market for the new Research Areas industrial market offer a holistic analysis, market size and forecast, Trends, growth drivers and challenges as well as a supplier analysis for about 25 suppliers.

To request an exclusive sample report for CRISPR and Cas Genes Market : https://www.verifiedmarketresearch.com/download-sample/?rid=40530&utm_source=PFS&utm_medium=001

Global CRISPR and Cas Genes Market research to 2020 provides a basic Overview of the industry including definitions, classifications, applications and structure of the industrial chain. The global CRISPR and Cas Genes Market report is provided for international markets as well as for development trends, competitive landscape analyses and the development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / Export consumption, supply and demand, costs, Price, Sales and gross margins.

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

This report examines the global CRISPR and Cas Genes Market and analyses and examines the IoT in Education development status and forecast in the US, EU, Japan, China, India and Southeast Asia. This report focuses on the highest players in the global CRISPR and Cas Genes Market .

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40530&utm_source=PFS&utm_medium=001

The scope of the report covers all major system technologies currently being implemented in the global IoT in Education industry. Market values are supported the Top User (public and private) supports the production of IoT in Education systems. CRISPR and Cas Genes Market manufacturers place orders as soon as they receive work orders from CRISPR and Cas Genes Market operators. Therefore, market figures are derived from the perspective of the top users taking into account their orders (CRISPR and Cas Genes Market operator) for the CRISPR and Cas Genes Market .

North America (USA, Canada and Mexico)

Europe (Germany, Great Britain, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia and Vietnam))

-South America (Brazil, etc.)

The Middle East and Africa (North Africa and GCC countries)

The CRISPR and Cas Genes Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

Market drivers

Increasing deforestation due to increasing demand for increasing raw materials

For a full, detailed list, see our report

Market Challenge

Risks associated with the use of IoT in Education

For a full, detailed list, see our report

Market Trend

Increasing consumer preference for IoT in EducationFor a full, detailed list, see our report

The global market research report of IoT in Education industry 2020 is distributed over several pages and contains exclusive Statistics, data, information, CRISPR and Cas Genes Market trends and details of the competitive landscape in this niche sector.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/crispr-and-cas-genes-market/?utm_source=PFS&utm_medium=001

-To analyze IoT in Education consumption (value and volume), product type and Application, History data from 2015 to 2020 and forecast.

-To understand the structure of the CRISPR and Cas Genes Market , identify the different sub-segments.

Focuses on the most important IoT in Education manufacturers to define, describe and analyze sales volume, value, market share, market competition landscape, STREBER analysis and development plans in the coming years.

To analyze the CRISPR and Cas Genes Market taking into account individual growth trends, future prospects and their contribution to the overall market

Detailed information on the key factors influencing the Expansion of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To analyze competitive developments such as extensions, agreements, product launches and acquisitions within the company

To strategically profile the main players and to comprehensively analyse their growth strategies.

The report also focuses on the worlds leading industry players in the global CRISPR and Cas Genes Market , providing information such as company profiles, product images and specifications, capacity, production, price, cost, revenue and contacting information. In addition, upstream raw materials and equipment as well as downstream demand analyses are managed. The global CRISPR and Cas Genes Market development trends and market channels are analyzed. Finally, the feasibility of the latest investment projects is evaluated and general research results are offered. With tables and figures to help analyze the global CRISPR and Cas Genes Market , this study provides important statistics on the state of the industry and can be a valuable guide and guidance for companies and individuals who are curious about the market.

This report provides a pinpoint analysis of the change in competitive dynamics

CRISPR and Cas Genes Market provides a forward-looking perspective on various factors that drive or inhibit market growth.

It includes a six-year forecast, which is assessed on the basis of expected market growth

Better understanding of the effects of specific conditions on the prevailing population of the CRISPR and Cas Genes Market .

To understand the most important product segments and their future

Transfer of more accurate information for clinical trials to determine research size and realistic recruitment for different countries

CRISPR and Cas Genes Market helps with sound business decisions by having complete insights into the market and analyzing market segments in depth

-To provide distinctive graphics and exemplary STREBER analysis of the most important market segments

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

More here:
CRISPR and Cas Genes Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2027 - Owned

A recently published market research report by Fact.MR on the CRISPR and Cas Genes Market depicts a crystal clear view of the market over the considered period of assessment (2020 2026). The global CRISPR and cas genes market study comes with an all in all compilation of the future, existing, and historical outlook of the market as well as the factors bringing in such growth for the market. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities, and threats of each CRISPR and cas genes market player in a comprehensive way. Further, the CRISPR and cas genes market report emphasizes the adoption pattern of the CRISPR and cas genes across various industries.

The existing trends, restraints, opportunities, and market drivers are studied thoroughly to offer a clear, 360-degree understanding of the existing landscape prevailing in the CRISPR and cas genes market. The research paints a detailed picture of how the market is likely to take shape in the coming years given the influence of current drivers, opportunities, and restraints. In this latest market research study published by Fact.MR, the analysts have taken into account the CRISPR and cas genes market from a local as well as global viewpoint.

Act Today to Succeed Tomorrow, Know the COVID-19 Impact, Request for Sample @https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The outbreak of novel coronavirus across the globe has changed the way about how we do business, it has resulted in both disadvantages and advantages for players operating in the CRISPR and cas genes market. A health crisis of enormous proportion, COVID-19 has emerged as a pandemic that would cause a restructuring of the world economy as well as social order. This outbreak is clearly going to characterize the coming era with fundamental schism. Many companies have shifted from their traditional methods of advertising during the lockdown period.

Taking help of this latest offering on the CRISPR and cas genes market by Fact.MR, the market players, suppliers, distributors, and other stakeholders can formulate innovative strategies based on their understanding of the pandemic and our report to expand their business and widen their base of customers. This research study by Fact.MR is likely to detail the factors that could impact the sales of products/ services in the global market landscape. The report is also likely to suggest avenues of growth that could boost sales in the post-pandemic era.

According to the market research report, the CRISPR and cas genes market is estimated to register a CAGR growth of 21.2% over the assessment period due to several key factors that is likely to influence the market, such as favorable regulatory policies, augmented spending on research and development. The analysts at Fact.MR makes use of the latest research methodologies while gathering data from credible and reliable sources, both primary and secondary, to prepare and present the market study.

In this CRISPR and cas genes market study, the following years are considered to project the market footprint:

The CRISPR and cas genes market report has answers to important questions, which include the following:

The CRISPR and cas genes market report covers the following regions:

On the basis of product type, the CRISPR and cas genes market report considers the following segments:

On the basis of end-use, the CRISPR and cas genes market report includes:

Ask for Regional Data of This Report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Prominent CRISPR and cas genes market players covered in the report contain:

The behavioral pattern of each of the market player, such as acquisitions, new product launches, partnerships, and mergers have been thoroughly studied to offer a detailed view of the competitive landscape of the CRISPR and cas genes market.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

See the rest here:
Scaling the COVID-19 Impact: Fact.MR Projects Staggering Growth in CRISPR and Cas Genes Market 2020 2026 - The Cloud Tribune

IndustryGrowthInsights (IGI) offers a detailed report on Global CRISPR Genome Editing Market. The report is a comprehensive research study that provides the scope of CRISPR Genome Editing market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in regions for the forecast period from 2020 to 2026. This report highlights key insights on the market focusing on the possible requirements of the clients and assisting them to make right decision about their business investment plans and strategies.

The CRISPR Genome Editing market report also covers an overview of the segments and sub-segmentations including the product types, applications, companies and regions. This report further includes the impact of COVID-19 on the market and explains dynamics of the market, future business impact, competition landscape of the companies, and the flow of the global supply and consumption. The report provides an in-depth analysis of the overall market structure of CRISPR Genome Editing and assesses the possible changes in the current as well as future competitive scenarios of the CRISPR Genome Editing market.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=136905

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies. IndustryGrowthInsights (IGI) is known for its data accuracy and granular market reports.

The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the CRISPR Genome Editing market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the CRISPR Genome Editing market.

Key companies that are covered in this report:

Editas MedicineCRISPR TherapeuticsHorizon DiscoverySigma-AldrichGenscriptSangamo BiosciencesLonza GroupIntegrated DNA TechnologiesNew England BiolabsOrigene TechnologiesTransposagen BiopharmaceuticalsThermo Fisher ScientificCaribou BiosciencesPrecision BiosciencesCellectisIntellia Therapeutics

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

Biotechnology CompaniesPharmaceutical CompaniesOthers

By Type:

Genetic EngineeringGene LibraryHuman Stem CellsOthers

As per the report, the CRISPR Genome Editing market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% through the forecast period (2020-2026). The report describes the current market trend of the CRISPR Genome Editing in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on CRISPR Genome Editing market.

You can buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=136905

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

CRISPR Genome Editing Market Overview

Global CRISPR Genome Editing Market Analysis and Forecast by Type

Global CRISPR Genome Editing Market Analysis and Forecast by Application

Global CRISPR Genome Editing Market Analysis and Forecast by Sales Channel

Global CRISPR Genome Editing Market Analysis and Forecast by Region

North America CRISPR Genome Editing Market Analysis and Forecast

Latin America CRISPR Genome Editing Market Analysis and Forecast

Europe CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Application

Middle East & Africa CRISPR Genome Editing Market Analysis and Forecast

Competition Landscape

Why you should buy this report?

This report offers a concise analysis of the CRISPR Genome Editing market for the last 5 years with historical data & more accurate prediction for upcoming 6 years on the basis of statistical information.

This report helps you to understand the market components by offering a cohesive framework of the key players and their competition dynamics as well as strategies.

The report is a complete guideline for the clients to arrive an informed business decision since it consists of a detailed information for better understandings of the current & future market situation.

The report also answers some of the key questions given below:

Which end-user is likely to play a crucial role in the development of the CRISPR Genome Editing market?

Which regional market is expected to dominate the CRISPR Genome Editing market in 2020-2026?

How is consumer consumption behavior impacting the business operations of market players in the current scenario of the CRISPR Genome Editing market?

If you have any questions on this report, please reach out to us @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=136905

About IndustryGrowthInsights (IGI):

We possess expertise in a variety of business intelligence domains. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://industrygrowthinsights.com

See original here:
CRISPR Genome Editing Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Market Research Vista

Global CRISPR Industry market Report 2020 presents critical information and factual data about the CRISPR Industry market, providing an overall statistical study of this market on the basis of market drivers, market limitations, and its future prospects. The widespread CRISPR Industry market opportunities and trends are also taken into consideration in CRISPR Industry industry. with growth trends, various stakeholders like investors, traders, suppliers, SWOT analysis Opportunities and Threat to the organization and others.

The CRISPR Industry market report comprises of the key trends which influence the industry growth with respect to the regional terrain and competitive arena. The study highlights the opportunities that will support the industry expansion in existing and untapped markets along with the challenges the business sphere will face. Besides this, the report also offers an intricate analysis of case studies including those of COVID-19 pandemic, with the aim to provide a clear picture of this industry vertical to all shareholders.

Pivotal pointers from COVID-19 impact assessment:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/158192

Analysis of the regional terrain:

Highlights of the CRISPR Industry market report:

Key Coverage of report:

Impact of the latest technological innovations on the CRISPR Industry market

Key growth strategies adopted by the prominent market players to address the challenges and restraints put forward by the COVID-19 pandemic

Historical and current trends likely to affect the overall market dynamics of the CRISPR Industry market

Growth assessment of the various market segments over the forecast timeline

Regional and global presence of major market players in the CRISPR Industry market

Table of Content:

1 CRISPR Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of CRISPR Industry market

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the CRISPR Industry industry

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

2.1 Market Overview

2.1.1 Global CRISPR Industry market Size, 2015 - 2020

2.1.2 Global CRISPR Industry market Size by Type, 2015 - 2020

2.1.3 Global CRISPR Industry market Size by Application, 2015 - 2020

2.1.4 Global CRISPR Industry market Size by Region, 2015 - 2025

2.2 Business Environment Analysis

2.2.1 Global COVID-19 Status and Economic Overview

2.2.2 Influence of COVID-19 Outbreak on CRISPR Industry Industry Development

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/158192

Original post:
Global CRISPR Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2025 - Express Journal

CRISPR And CRISPR-Associated (Cas) Genes Market report tracks the data since 2015 and is one of the most detailed reports. It also contains data varying according to region and country. The insights in the report are easy to understand and include pictorial representations.

Get Free Sample PDF Copy of CRISPR And CRISPR-Associated (Cas) Genes Market with Figures, Graphs and Tocs:www.reportsnreports.com/contactme=2846167

The report also includes the impact of ongoing global crisis i.e.COVID-19on the CRISPR And CRISPR-Associated (Cas) Genes Market and what the future holds for it.

The published report is designed using a vigorous and thorough research methodology andReportsnReportsis also known for its data accuracy and granular market reports.

Summary

Market OverviewThe global CRISPR And CRISPR-Associated (Cas) Genes market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 38.3% in the forecast period of 2020 to 2025 and will expected to reach USD 2685.5 million by 2025, from USD 734.5 million in 2019.The CRISPR And CRISPR-Associated (Cas) Genes market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentationCRISPR And CRISPR-Associated (Cas) Genes market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value.

This analysis can help you expand your business by targeting qualified niche markets.By Type, CRISPR And CRISPR-Associated (Cas) Genes market has been segmented into Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering,.By Application, CRISPR And CRISPR-Associated (Cas) Genes has been segmented into Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes,.

Regions and Countries Level AnalysisRegional analysis is another highly comprehensive part of the research and analysis study of the global CRISPR And CRISPR-Associated (Cas) Genes market presented in the report. This section sheds light on the sales growth of different regional and country-level CRISPR And CRISPR-Associated (Cas) Genes markets.

For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market.The report offers in-depth assessment of the growth and other aspects of the CRISPR And CRISPR-Associated (Cas) Genes market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia,. It also throws light on the progress of key regional CRISPR And CRISPR-Associated (Cas) Genes markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Competitive Landscape and CRISPR And CRISPR-Associated (Cas) Genes Market Share AnalysisCRISPR And CRISPR-Associated (Cas) Genes competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, CRISPR And CRISPR-Associated (Cas) Genes sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the CRISPR And CRISPR-Associated (Cas) Genes sales, revenue and market share for each player covered in this report.The major players covered in CRISPR And CRISPR-Associated (Cas) Genes are: Caribou Biosciences, Thermo Fisher Scientific, Merck KGaA, Addgene, Takara Bio USA, CRISPR THERAPEUTICS, Intellia Therapeutics, Editas Medicine, Mirus Bio LLC, Horizon Discovery Group, GE Healthcare Dharmacon,. Among other players domestic and global, CRISPR And CRISPR-Associated (Cas) Genes market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately.

Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe CRISPR And CRISPR-Associated (Cas) Genes product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of CRISPR And CRISPR-Associated (Cas) Genes, with price, sales, revenue and global market share of CRISPR And CRISPR-Associated (Cas) Genes in 2018 and 2019.Chapter 3, the CRISPR And CRISPR-Associated (Cas) Genes competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the CRISPR And CRISPR-Associated (Cas) Genes breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, CRISPR And CRISPR-Associated (Cas) Genes market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe CRISPR And CRISPR-Associated (Cas) Genes sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Enquire for More Information CRISPR And CRISPR-Associated (Cas) Genes Market:www.reportsnreports.com/contactme=2846167

The global CRISPR And CRISPR-Associated (Cas) Genes Market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period.

The research study on the global CRISPR And CRISPR-Associated (Cas) Genes Market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

This report studies the CRISPR And CRISPR-Associated (Cas) Genes Market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CRISPR And CRISPR-Associated (Cas) Genes Market by product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question.

The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Full Report available @www.reportsnreports.com/purchasme=2846167

The report helps to identify the main CRISPR And CRISPR-Associated (Cas) Genes Market players. It assists in analyzing CRISPR And CRISPR-Associated (Cas) Genes Market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details.

The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get CRISPR And CRISPR-Associated (Cas) Genes Market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Link:
CRISPR And CRISPR-Associated (Cas) Genes Market analysis and forecast to 2026 investigated in the latest research - WhaTech Technology and Markets...

LOS ANGELES, United States: QY Research has recently published a report, titled Global and China CRISPR-Based Therapeutics Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Global and China CRISPR-Based Therapeutics market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Global and China CRISPR-Based Therapeutics market include: , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2027764/global-and-china-crispr-based-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Global and China CRISPR-Based Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Global and China CRISPR-Based Therapeutics Market Segment By Type:

Genome EditingGenetic EngineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering CRISPR-Based Therapeutics

Global Global and China CRISPR-Based Therapeutics Market Segment By Application:

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes Based on

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Global and China CRISPR-Based Therapeutics market.

Key companies operating in the global Global and China CRISPR-Based Therapeutics market include , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2027764/global-and-china-crispr-based-therapeutics-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global CRISPR-Based Therapeutics Market Size Growth Rate by Type: 2020 VS 20261.2.2 Genome Editing1.2.3 Genetic Engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 Market by Application1.3.1 Global CRISPR-Based Therapeutics Market Share by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global CRISPR-Based Therapeutics Market Perspective (2015-2026)2.2 Global CRISPR-Based Therapeutics Growth Trends by Regions2.2.1 CRISPR-Based Therapeutics Market Size by Regions: 2015 VS 2020 VS 20262.2.2 CRISPR-Based Therapeutics Historic Market Share by Regions (2015-2020)2.2.3 CRISPR-Based Therapeutics Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top CRISPR-Based Therapeutics Players by Market Size3.1.1 Global Top CRISPR-Based Therapeutics Players by Revenue (2015-2020)3.1.2 Global CRISPR-Based Therapeutics Revenue Market Share by Players (2015-2020)3.2 Global CRISPR-Based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by CRISPR-Based Therapeutics Revenue3.4 Global CRISPR-Based Therapeutics Market Concentration Ratio3.4.1 Global CRISPR-Based Therapeutics Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by CRISPR-Based Therapeutics Revenue in 20193.5 Key Players CRISPR-Based Therapeutics Area Served3.6 Key Players CRISPR-Based Therapeutics Product Solution and Service3.7 Date of Enter into CRISPR-Based Therapeutics Market3.8 Mergers & Acquisitions, Expansion Plans 4 CRISPR-Based Therapeutics Breakdown Data by Type (2015-2026)4.1 Global CRISPR-Based Therapeutics Historic Market Size by Type (2015-2020)4.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Type (2021-2026) 5 CRISPR-Based Therapeutics Breakdown Data by Application (2015-2026)5.1 Global CRISPR-Based Therapeutics Historic Market Size by Application (2015-2020)5.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America CRISPR-Based Therapeutics Market Size (2015-2026)6.2 North America CRISPR-Based Therapeutics Market Size by Type (2015-2020)6.3 North America CRISPR-Based Therapeutics Market Size by Application (2015-2020)6.4 North America CRISPR-Based Therapeutics Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe CRISPR-Based Therapeutics Market Size (2015-2026)7.2 Europe CRISPR-Based Therapeutics Market Size by Type (2015-2020)7.3 Europe CRISPR-Based Therapeutics Market Size by Application (2015-2020)7.4 Europe CRISPR-Based Therapeutics Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China CRISPR-Based Therapeutics Market Size (2015-2026)8.2 China CRISPR-Based Therapeutics Market Size by Type (2015-2020)8.3 China CRISPR-Based Therapeutics Market Size by Application (2015-2020)8.4 China CRISPR-Based Therapeutics Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan CRISPR-Based Therapeutics Market Size (2015-2026)9.2 Japan CRISPR-Based Therapeutics Market Size by Type (2015-2020)9.3 Japan CRISPR-Based Therapeutics Market Size by Application (2015-2020)9.4 Japan CRISPR-Based Therapeutics Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia CRISPR-Based Therapeutics Market Size (2015-2026)10.2 Southeast Asia CRISPR-Based Therapeutics Market Size by Type (2015-2020)10.3 Southeast Asia CRISPR-Based Therapeutics Market Size by Application (2015-2020)10.4 Southeast Asia CRISPR-Based Therapeutics Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Company Details11.1.2 Caribou Biosciences Business Overview11.1.3 Caribou Biosciences CRISPR-Based Therapeutics Introduction11.1.4 Caribou Biosciences Revenue in CRISPR-Based Therapeutics Business (2015-2020))11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Company Details11.2.2 Addgene Business Overview11.2.3 Addgene CRISPR-Based Therapeutics Introduction11.2.4 Addgene Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Company Details11.3.2 CRISPR THERAPEUTICS Business Overview11.3.3 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Introduction11.3.4 CRISPR THERAPEUTICS Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Company Details11.4.2 Merck KGaA Business Overview11.4.3 Merck KGaA CRISPR-Based Therapeutics Introduction11.4.4 Merck KGaA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Company Details11.5.2 Mirus Bio LLC Business Overview11.5.3 Mirus Bio LLC CRISPR-Based Therapeutics Introduction11.5.4 Mirus Bio LLC Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Company Details11.6.2 Editas Medicine Business Overview11.6.3 Editas Medicine CRISPR-Based Therapeutics Introduction11.6.4 Editas Medicine Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Company Details11.7.2 Takara Bio USA Business Overview11.7.3 Takara Bio USA CRISPR-Based Therapeutics Introduction11.7.4 Takara Bio USA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Company Details11.8.2 Thermo Fisher Scientific Business Overview11.8.3 Thermo Fisher Scientific CRISPR-Based Therapeutics Introduction11.8.4 Thermo Fisher Scientific Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Company Details11.9.2 Horizon Discovery Group Business Overview11.9.3 Horizon Discovery Group CRISPR-Based Therapeutics Introduction11.9.4 Horizon Discovery Group Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Company Details11.10.2 Intellia Therapeutics Business Overview11.10.3 Intellia Therapeutics CRISPR-Based Therapeutics Introduction11.10.4 Intellia Therapeutics Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.10.5 Intellia Therapeutics Recent Development11.11 GE Healthcare Dharmacon10.11.1 GE Healthcare Dharmacon Company Details10.11.2 GE Healthcare Dharmacon Business Overview10.11.3 GE Healthcare Dharmacon CRISPR-Based Therapeutics Introduction10.11.4 GE Healthcare Dharmacon Revenue in CRISPR-Based Therapeutics Business (2015-2020)10.11.5 GE Healthcare Dharmacon Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post here:
Trending Now: CRISPR-Based Therapeutics Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026|, Caribou...

Researchers at the University of Copenhagen in a new study presented the largest and most complex CRISPR system. Scientists believe that this system can find applications in biomedicine and biotechnology. Their work is featured in the scientific journal Molecular Cell.

CRISPR technology can be used to edit genes and revolutionized the scientific world when it was first introduced. CRISPR-Cas9 is probably the best-known CRISPR system and is widely known as gene scissors.

This is just one of many CRISPR systems in existence.

Now researchers at the University of Copenhagen (UCPH) have mapped and analyzed the atomic structure of one of the most complex CRISPR systems identified to date.

Scientists have disassembled the largest and most complex CRISPR-Cas complex seen so far. They now understand how this system works at the molecular level, said co-author Guillermo Montoya, professor at the Novo Nordisk Foundations Center for Protein Research at the University of Copenhagen (NNF CPR). Scientists have studied a complex called Cmr-, which belongs to a subgroup of so-called type III-B CRISPR-Cas complexes. The new results have already been presented to the public.

In the new study, the researchers examined the role of Cmr in the immune system and the mechanisms underlying its immune response against various bacteriophages, as well as how it is regulated.

The Cmr system, mapped by scientists in the new study, may, among other things, remove single-stranded RNA and DNA, although this will be quite difficult. But in the future, the Cmr system may still be the key to understanding the immune response of bacteria, and it may find applications in the fight against antibiotic resistance.

Read this article:
Scientists have mapped and analyzed the atomic structure of CRISPR-Cas - FREE NEWS